VRCI.L
Verici Dx plc [VRCI.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VRCI.L Stock Summary
Top 10 Correlated ETFs
VRCI.L
Top 10 Correlated Stocks
VRCI.L
In the News
VRCI.L Financial details
Company Rating
-
Market Cap
18.82M
Income
-11.21M
Revenue
19K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
30 May 2024
P/E
-1.98
Forward P/E
-
PEG
-1.66
P/S
-
P/B
1.96
P/C
-
P/FCF
-2.05
Quick Ratio
4.68
Current Ratio
4.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.07
EPS next Y
-
EPS next Q
-
EPS this Y
17.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-79%
ROE
-97%
ROC
-0.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.5-19.0
52W High
-98.16%
52W Low
-93%
RSI
12
Rel Volume
1.3
Avg Volume
331.99K
Volume
432K
Perf Week
-6.67%
Perf Month
-17.65%
Perf Quarter
-51.72%
Perf Half Y
-54.84%
-
-
-
-
Beta
1.484
-
-
Volatility
0.01%, 0.02%
Prev Close
0%
Price
0.35
Change
16.67%
Company Profile
- Volume Average 331.99K
- Market Capitalization 18.82M
- Employee 14
- CEO Ms. Sara Barrington A.C.A., A.C.I.M.
- Headquarters Penarth,GB
- IPO Date 2020-11-03
-
Website
https://www.vericidx.com 
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
